Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 14:3:259.
doi: 10.3389/fimmu.2012.00259. eCollection 2012.

Targeting PKCθ in alloreactivity and graft-versus-host-disease: unanswered questions and therapeutic potential

Crystina C Bronk  1 , Xue-Zhong Yu, Amer A Beg
Affiliations

Targeting PKCθ in alloreactivity and graft-versus-host-disease: unanswered questions and therapeutic potential

Crystina C Bronk et al. Front Immunol. .

Abstract

Protein kinase C isoform θ (PKCθ) is a key modulator of TCR signaling and mediates activation of NF-κB, NF-AT, and AP-1 transcription factors. Although in vitro studies of PKCθ(-/-) T cells have shown impaired activation responses, in vivo studies indicate that PKCθ requirement is not universal. While PKCθ is important in induction of experimentally induced autoimmune diseases in mice and generation of Th2 responses, it is not essential for induction of T cell proliferative and cytotoxic responses against influenza virus, LCMV, and vaccinia virus. The context-specific involvement of PKCθ in T cell responses suggests that inhibition of PKCθ may be beneficial in some but not all situations. In the bone marrow transplantation (BMT) setting, we have shown that graft-versus-host-disease (GVHD) cannot be induced in the absence of PKCθ. However, graft-versus-leukemia effects and T cell ability to clear virus infection remains intact. Therefore, PKCθ is a potential therapeutic target in BMT, inhibition of which may prevent GVHD while retaining anti-tumor and anti-infection responses.

Keywords: T cell activation; alloreactivity; anti-tumor effect; graft-versus-host-disease; protein kinase C.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Anderson K., Fitzgerald M., Dupont M., Wang T., Paz N., Dorsch M., Healy A., Xu Y., Ocain T., Schopf L., Jaffee B., Picarella D. (2006). Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases. Autoimmunity 39 469–478 - PubMed
    1. Appelbaum F. R. (2001). Haematopoietic cell transplantation as immunotherapy. Nature 411 385–389 - PubMed
    1. Baier G., Wagner J. (2009). PKC inhibitors: potential in T cell-dependent immune diseases. Curr. Opin. Cell Biol. 21 262–267 - PubMed
    1. Barouch-Bentov R., Lemmens E. E., Hu J., Janssen E. M., Droin N. M., Song J., Schoenberger S. P., Altman A. (2005). Protein kinase C-theta is an early survival factor required for differentiation of effector CD8+ T cells. J. Immunol. 175 5126–5134 - PubMed
    1. Berg-Brown N. N., Gronski M. A., Jones R. G., Elford A. R., Deenick E. K., Odermatt B., Littman D. R., Ohashi P. S. (2004). PKCtheta signals activation versus tolerance in vivo. J. Exp. Med. 199 743–752 - PMC - PubMed

LinkOut - more resources